What is HC Wainwright’s Forecast for CRVS FY2030 Earnings?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Research analysts at HC Wainwright reduced their FY2030 EPS estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Monday, August 10th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of $0.67 for the year, down from their prior estimate of $0.74. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.70) per share.

A number of other analysts have also commented on the company. Wall Street Zen lowered Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings upgraded Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. LADENBURG THALM/SH SH upgraded shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th. Finally, The Goldman Sachs Group initiated coverage on shares of Corvus Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $40.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.33.

Corvus Pharmaceuticals Stock Down 1.3%

Shares of CRVS opened at $13.74 on Tuesday. Corvus Pharmaceuticals has a twelve month low of $4.26 and a twelve month high of $26.95. The company has a market capitalization of $1.16 billion, a P/E ratio of -22.52 and a beta of 0.87. The firm has a 50 day moving average of $13.44 and a 200 day moving average of $15.33.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, August 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.03).

Insider Buying and Selling

In other news, Director David Scott Moore bought 21,700 shares of the stock in a transaction on Thursday, June 11th. The shares were bought at an average price of $11.53 per share, with a total value of $250,201.00. Following the completion of the acquisition, the director owned 21,700 shares in the company, valued at $250,201. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 19.70% of the company’s stock.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in Corvus Pharmaceuticals during the second quarter valued at approximately $106,654,000. MPM Bioimpact LLC purchased a new stake in shares of Corvus Pharmaceuticals in the 4th quarter worth $21,126,000. Commodore Capital LP bought a new position in Corvus Pharmaceuticals in the 1st quarter worth $33,045,000. State Street Corp lifted its position in Corvus Pharmaceuticals by 177.1% during the fourth quarter. State Street Corp now owns 2,788,223 shares of the company’s stock valued at $21,469,000 after purchasing an additional 1,781,904 shares in the last quarter. Finally, Perceptive Advisors LLC grew its holdings in Corvus Pharmaceuticals by 231.1% during the first quarter. Perceptive Advisors LLC now owns 2,292,441 shares of the company’s stock valued at $33,538,000 after purchasing an additional 1,600,000 shares during the period. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.